Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CDYL2 | Q8N8U2 | 6/20 | 0.43 |
| ▸ | CBX7 | O95931 | 4/20 | 0.43 |
| ▸ | CBX8 | Q9HC52 | 4/20 | 0.43 |
| ▸ | CBX4 | O00257 | 3/20 | 0.41 |
| ▸ | TLR2 | O60603 | 3/20 | 0.40 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.40 |
| ▸ | CBX6 | O95503 | 1/20 | 0.39 |
| ▸ | CBX2 | Q14781 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29129094 | 0.83 | KMT2A (0.43) | KMT2ATLR2TLR1TPSAB1 | |
| SCHEMBL29613476 | 0.82 | KMT2A (0.52) | KMT2ATLR2TLR1 | |
| SCHEMBL29613473 | 0.81 | CDYL2 (0.67) | CDYL2CBX7CBX8CBX4CBX6 | |
| SCHEMBL29613403 | 0.81 | KMT2A (0.41) | KMT2ACDYL2CBX7CBX8CBX4 | |
| SCHEMBL29613495 | 0.78 | TLR2 (0.47) | KMT2ACDYL2CBX7CBX8CBX4 | |
| SCHEMBL29613492 | 0.78 | TLR2 (0.47) | KMT2ACDYL2CBX7CBX8CBX4 | |
| SCHEMBL28563576 | 0.78 | KMT2A (0.49) | KMT2ATLR2 | |
| SCHEMBL28563579 | 0.78 | KMT2A (0.49) | KMT2ATLR2 | |
| SCHEMBL29613497 | 0.78 | KMT2A (0.53) | KMT2ATLR2TLR1CA1CA2 | |
| SCHEMBL29613500 | 0.78 | KMT2A (0.50) | KMT2ATLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240166693-A1 | METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPY 1 | Design Therapeutics, Inc. | 2024-05-23 | — | — | US | disclosed |
| EP-4259133-A1 | METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPHY 1 | Design Therapeutics, Inc. (US) | 2023-10-18 | — | — | EP | disclosed |
| WO-2022126000-A1 | METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPHY 1 | Design Therapeutics, Inc. (US) | 2022-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240166693-A1 | METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPY 1 | MTPN, DMPK, MBNL1 | KMT2A 2132/4885CDYL2 545/4885CBX7 1704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.